pdufa.bio
CalendarReadoutsDevicesDecisionsApprovals/yrTrial oddsLearnResearchMethodologyCoveragePricing
Home › PDUFA Calendar › ABBV

ABBV PDUFA Date: RINVOQ (upadacitinib)

FDA decision (PDUFA) target 2026-12-31 · AbbVie Inc. · Non-segmental vitiligo (NSV)
More Immunology & Inflammation FDA decisions →All December 2026 PDUFA dates →

The story

RINVOQ (upadacitinib) is under FDA review to treat Non-segmental vitiligo (NSV).
Full PDUFA calendar ->Every upcoming FDA decision date, by monthNRXP . 2026-07-29Same area: Neurology . KETAFREELNTH-florquinitau . 2026-08-13Same area: Neurology . Florquinitau (MK-6240)EXEL . 2026-12-03Same month decision . XL092 with atezolizumab
Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

ABBV run-up into the PDUFA (last ~120 days)

$236.19$197.38
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-31
Drug / candidateRINVOQ (upadacitinib)
IndicationNon-segmental vitiligo (NSV)
CompanyAbbVie Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT04927975

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the ABBV PDUFA date?
The FDA PDUFA target date for ABBV (AbbVie Inc.) is 2026-12-31 for RINVOQ (upadacitinib). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is ABBV's drug RINVOQ (upadacitinib)?
RINVOQ (upadacitinib) is AbbVie Inc.'s candidate under FDA review for Non-segmental vitiligo (NSV).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.